HOME
Leading the way to a cure

Lupus News

Tacrolimus Therapy Effective, Safe for Patients with Lupus Nephritis

December 28, 2012
Low-dose tacrolimus therapy for patients with refractory lupus nephritis who were resistant to cyclophosphamide was effective and safe, according to study results.

See full story >


Bone Marrow Abnormalities Common Among Lupus Patients with Peripheral Cytopenia

December 26, 2012
Researchers in Thailand conducted the prospective, cross-sectional, analytic study of 41 patients (median age, 30 years; 95.1% women) who had systemic lupus erythematosus (SLE) plus the presence of...

See full story >


Clear Channel Throws Annual Jingle Balls

November 20, 2012
Clear Channel Media and Entertainment will celebrate the holiday season with its series of annual holiday concerts throughout the country. This year, stations are collaborating with nonprofits,...

See full story >


Drug Combo Offers Long-Term Benefits in SLE

November 18, 2012
WASHINGTON -- An 18-month treatment with the combination of rituximab and cyclophosphamide (Cytoxan) stopped progression of systemic lupus erythematosus (SLE) for at least 3 years, researchers here.

See full story >


Long-Term Efficacy and Safety Results of Epratuzumab in Lupus Presented at Rheumatology Conference

November 12, 2012
WASHINGTON, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...

See full story >


Items 86 - 90 of 100  Previous11121314151617181920Next

1.5 million

people in the U.S. have Lupus.

100 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.